4.3 Article

Blood Pressure Control by Drug Group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

期刊

JOURNAL OF CLINICAL HYPERTENSION
卷 10, 期 10, 页码 751-760

出版社

WILEY
DOI: 10.1111/j.1751-7176.2008.00015.x

关键词

-

资金

  1. National Heart, Lung, and Blood Institute [N0.1-HC-35130]
  2. National Institutes of Health, US Department of Health and Human Services, Bethesda, MD
  3. AstraZeneca
  4. GlaxoSmithKline
  5. Novartis

向作者/读者索取更多资源

Blood pressure (BP) control rates and number of antihypertensive medications were compared (average follow-up, 4.9 years) by randomized groups: chlorthalidone, 12.5-25 mg/d (n=15,255), amlodipine 2.5-10 mg/d (n=9048), or lisinopril 10-40 mg/d (n=9054) in a randomized double-blind hypertension trial. Participants were hypertensives aged 55 or older with additional cardiovascular risk factor(s), recruited from 623 centers. Additional agents from other classes were added as needed to achieve BP control. BP was reduced from 145/83 mm Hg (27% control) to 134/76 mm Hg (chlorthalidone, 68% control), 135/75 mm Hg (amlodipine, 66% control), and 136176 mm Hg (lisinopril, 61% control) by 5 years; the mean number of drugs prescribed was 1.9, 2.0, and 2.1, respectively. Only 28% (chlorthalidone), 24% (amlodipine), and 24% (lisinopril) were controlled on monotherapy. BP control was achieved in the majority of each randomized group-a greater proportion with chlorthalidone. Over time, providers and patients should expect multidrug therapy to achieve BP < 140/90 mm Hg in a majority of patients. J Clin Hypertens (Greenwich). 2008;1.0:751-760. (c) 2008 Le Jacq

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据